Jynneos, a current vaccine against orthopoxviruses such as smallpox and mpox virus, elicits only modest antibody responses, highlighting the need to search for more immunogenic vaccines or treatments. The global outbreak of mpox virus infections in 2022 lent urgency to this challenge.
Shattuck Labs Inc. has reported that its IND from the U.S. FDA for SL-325 for the treatment of inflammatory bowel disease is now in effect. The company expects to commence a phase I trial in healthy volunteers in the third quarter of this year.
One of the major obstacles to treating neurological disorders such as Alzheimer’s disease is the blood-brain barrier: drugs that are injected into the circulation usually do not enter the brain effectively. Researchers at Denali Therapeutics Inc., Biogen Inc. and the University of Minnesota have devised a vehicle for transporting antibodies against amyloid-β that can bypass the blood-brain barrier by binding to the transferrin receptor, which is expressed much more abundantly in capillaries than in arteries.
Mabylon AG has raised a total of CHF30 million (US$37 million) to advance its pipeline and support its work using human-derived, multi-specific antibodies for the treatment of allergies. The funding combines equity investment and a convertible loan.
Casi Pharmaceuticals Inc. announced the U.S. FDA has cleared its IND application for CID-103, a monoclonal antibody targeting CD-38 for the prevention of antibody-mediated rejection (AMR) of kidney allografts. The company plans to initiate a phase I study in adults with active and chronic active renal allograft AMR.
GSK plc scientists have presented findings from studies on the therapeutic potential of GSK-5862611, an anti-Sortilin antibody, in addressing neurodegenerative disease mechanisms linked to the TDP43 G298S mutation.
Immunitas Therapeutics Inc. has revealed preclinical data supporting development of its potentially first-in-class, fully human anti-CD161 antibody, IMT-380. CD161-expressing T-cell subsets have been implicated in autoimmune diseases due to their production of inflammatory cytokines and presence in inflamed tissues.
Activating apoptosis of tumor cells by binding a soluble form of the membrane protein TRAIL to its surface receptors DR4 and DR5 on the tumor surface shows promise as a cancer therapy, but the ligand on its own has only a minutes-long half-life and does not strongly activate the receptors.
Chugai Pharmaceutical Co. Ltd. and Gero Pte Ltd. have entered into a joint research and license agreement to develop novel therapies for age-related diseases. Chugai will create novel antibody-drug candidates for new drug targets discovered by Gero using its AI target discovery platform.
Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive global rights to a preclinical claudin 3-targeting monoclonal antibody, ABN-501, and the potential to license four more protein targeting antibodies.
RSS
